Viking Therapeutics (VKTX) Current Leases (2019 - 2026)
Viking Therapeutics (VKTX) posted Current Leases of $161000.0 for Q2 2026, up 17.52% sequentially from $137000.0 in Q4 2025, and down 65.6% YoY from $468000.0 in Q2 2025.
Powered by 
Analysis
Viking Therapeutics (VKTX) Current Leases (2019 - 2026) Analysis & Trends
Viking Therapeutics has reported Current Leases for 8 years, with the latest figure at $161000.0 in Q2 2026.
- Quarterly Current Leases fell 65.6% year-over-year to $161000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $161000.0 (down 65.6% YoY) and the FY2025 annual result came in at $137000.0, down 71.98% from the prior year.
- Current Leases climbed to $161000.0 in Q2 2026 per VKTX's latest filing, from $137000.0 in the prior quarter.
- Over five years, Current Leases peaked at $498000.0 in Q1 2025 and troughed at $137000.0 in Q4 2025.
- A 5-year average of $328823.5 and a median of $319000.0 in 2023 frame the typical range for Current Leases.
- The sharpest annual moves came in 2022 and 2025: Current Leases soared 948.28% in 2022, then slumped 71.98% in 2025.
- Over 5 years, Current Leases stood at $304000.0 in 2022, then rose by 6.58% to $324000.0 in 2023, then jumped by 50.93% to $489000.0 in 2024, then plunged by 71.98% to $137000.0 in 2025, then climbed by 17.52% to $161000.0 in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $161000.0, $137000.0, and $437000.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 11.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 16.75 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 21.95 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Viking Therapeutics | 4.06 Bn | 4.06 Bn | - | 161,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 161,000.00 |
| Dec 31, 2025 | 137,000.00 |
| Sep 30, 2025 | 437,000.00 |
| Jun 30, 2025 | 468,000.00 |
| Mar 31, 2025 | 498,000.00 |
| Dec 31, 2024 | 489,000.00 |
| Sep 30, 2024 | 480,000.00 |
| Jun 30, 2024 | 334,000.00 |
| Mar 31, 2024 | 329,000.00 |
| Dec 31, 2023 | 324,000.00 |
| Sep 30, 2023 | 319,000.00 |
| Jun 30, 2023 | 314,000.00 |
| Mar 31, 2023 | 309,000.00 |
| Dec 31, 2022 | 304,000.00 |
| Sep 30, 2022 | 299,000.00 |
| Jun 30, 2022 | 238,000.00 |
| Mar 31, 2022 | 150,000.00 |
| Dec 31, 2021 | 29,000.00 |
| Sep 30, 2021 | 115,000.00 |
| Jun 30, 2021 | 198,000.00 |